School of Social and Community Medicine, University of Bristol, Canynge Hall 39 Whatley Road, Bristol BS8 2PS, UK.
BMC Pharmacol Toxicol. 2014 Sep 30;15:54. doi: 10.1186/2050-6511-15-54.
Psychiatric adverse drug reactions (ADRs) are distressing for patients and have important public health implications. We identified the drugs with the most frequent spontaneous reports of depression, and fatal and non-fatal suicidal behaviour to the UK's Yellow Card Scheme from 1998 to 2011.
We obtained Yellow Card data from the Medicines and Healthcare products Regulatory Agency for the drugs with the most frequent spontaneous reports of depression and suicidal behaviour from 1964 onwards. Prescribing data were obtained from the NHS Information Centre and the Department of Health. We examined the frequency of reports for drugs and estimated rates of reporting of psychiatric ADRs using prescribing data as proxy denominators from 1998 to 2011, as prescribing data were not available prior to 1998.
There were 110 different drugs with ≥ 20 reports of depression, 58 with ≥ 10 reports of non-fatal suicidal behaviour and 33 with ≥ 5 reports of fatal suicidal behaviour in the time period. The top five drugs with the most frequent reports of depression were the smoking cessation medicines varenicline and bupropion, followed by paroxetine (a selective serotonin reuptake inhibitor), isotretinoin (used in acne treatment) and rimonabant (a weight loss drug). Selective serotonin reuptake inhibitors, varenicline and the antipsychotic medicine clozapine were included in the top five medicines with the most frequent reports of fatal and non-fatal suicidal behaviour. Medicines with the highest reliably measured reporting rates of psychiatric ADRs per million prescriptions dispensed in the community included rimonabant, isotretinoin, mefloquine (an antimalarial), varenicline and bupropion. Robust denominators for community prescribing were not available for two drugs with five or more suicide reports, efavirenz (an antiretroviral medicine) and clozapine.
Depression and suicide-related ADRs are reported for many nervous system and non-nervous system drugs. As spontaneous reports cannot be used to determine causality between the drug and the ADR, psychiatric ADRs which can cause significant public alarm should be specifically assessed and reported in all randomised controlled trials.
精神药物不良反应(ADR)给患者带来痛苦,并对公共卫生具有重要影响。我们确定了自 1998 年至 2011 年期间向英国黄卡计划报告的最常见致抑郁药物、致死性和非致死性自杀行为的药物。
我们从药品和保健产品监管局获取了自 1964 年以来报告最频繁致抑郁和自杀行为的药物的黄卡数据。处方数据从国民保健服务信息中心和卫生部获得。我们检查了药物报告的频率,并使用 1998 年至 2011 年的处方数据作为代理分母来估计精神 ADR 的报告率,因为在 1998 年之前没有处方数据。
在研究期间,有 110 种不同药物报告了 20 次以上的抑郁,58 种药物报告了 10 次以上的非致死性自杀行为,33 种药物报告了 5 次以上的致死性自杀行为。报告最频繁的抑郁药物前五名是戒烟药物伐伦克林和安非他酮,其次是帕罗西汀(一种选择性 5-羟色胺再摄取抑制剂)、异维 A 酸(用于治疗痤疮)和氯氮平(一种抗精神病药物)。选择性 5-羟色胺再摄取抑制剂、伐伦克林和抗精神病药物氯氮平被列入报告最频繁的致死性和非致死性自杀行为的前五种药物。在社区分发的每百万处方中,精神 ADR 报告率最高的药物包括利莫那班、异维 A 酸、甲氟喹(一种抗疟药)、伐伦克林和安非他酮。有两种药物报告了 5 次或更多自杀事件,其社区处方的可靠分母无法获得,这两种药物分别是依非韦伦(一种抗逆转录病毒药物)和氯氮平。
许多神经系统和非神经系统药物都报告了抑郁和与自杀相关的 ADR。由于自发报告不能用于确定药物与 ADR 之间的因果关系,因此应在所有随机对照试验中专门评估和报告可能引起公众严重警惕的精神 ADR。